Comparison of female breast cancer between Russia and Germany: A population-based study on time trends and stage at diagnosis |
| |
| Affiliation: | 1. Epidemiology of Transition, Heidelberg Institute of Global Health, University Hospital Heidelberg, 69120 Heidelberg, Germany;2. Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, Trotsky av. 51, Arkhangelsk, Russia;3. Population Cancer Register of the Tomsk Region, 634050 Tomsk, Russia;4. Tomsk Regional Cancer Center, 634050 Tomsk, Russia;5. Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences (RAS), 634050 Tomsk, Russia;6. Brandenburg Medical School Theodor Fontane, Institute of Social Medicine and Epidemiology, 14770 Brandenburg an der Havel, Germany;7. Brandenburg Medical School Theodor Fontane, Faculty of Health Sciences Brandenburg, Karl-Liebknecht-Str. 24-25, 14467 Potsdam, Germany;1. Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA;2. Biomedical Statistics Research Core, University of Vermont, Burlington, VT, USA;3. Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA;1. Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain;2. Tobacco Control Unit, Cancer Prevention and Control Program, Institut Català d′Oncologia, L′Hospitalet de Llobregat, Barcelona, Spain;3. Tobacco Control Research Group, Epidemiology, public health, cancer prevention and palliative care program, Institut d′Investigació Biomèdica de Bellvitge - IDIBELL, L′Hospitalet de Llobregat, Spain;4. School of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain;5. Center for Biomedical Research in Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain;6. Group of Integrative Pharmacology and Systems Neuroscience, Neurosciences Programme, IMIM (Hospital del Mar Medical Research Institute), Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain;7. Addictions Unit, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain;8. Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain;1. Department of Ultrasonography, Xin Hua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Chongming Branch, No. 25 Nanmen Road, Chongming, Shanghai 202150, China;2. The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China;3. Community Health Service Center, No. 59 Fengnan Road, Changxing town, Chongming district, Shanghai 201913, China;4. Department of Cancer prevention, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Shanghai 200032, China;5. Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Er Road, Shanghai 200025, China;1. Albany Medical College, 43 New Scotland Avenue, Albany, NY 12208, USA;2. Department of Neuroscience and Experimental Therapeutics, Albany Medical College, 43 New Scotland Avenue, Albany, NY 12208, USA;3. Department of Gastroenterology, Albany Medical Center Hospital, 43 New Scotland Avenue, Albany, NY 12208, USA;1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China;2. Hotan District People’s Hospital, Hotan, Xinjiang 848000, China;3. Hospital Sultanah Aminah Johor Bahru, Malaysia;4. Universiti Kebangsaan Malaysia, Malaysia;5. Hospital Tuanku Ja’afar Seremban, Malaysia;6. Hospital Sultanah Bahiyah Alor Setar, Malaysia;7. Penang General Hospital, Malaysia;8. Hospital Sungai Buloh, Malaysia;1. Hospital Sultanah Aminah, Johor Bahru, Malaysia;2. Monash University Malaysia, Malaysia |
| |
| Abstract: | ObjectivesWhile a mammography-screening program (MSP) is being offered systematically in Germany since 2009, the dispanserizatsiya has been implemented in Russia since 2013. This study examined trends of stage at breast cancer diagnosis in two Russian regions and compared the results with the development in Germany. In addition, we aimed to gain further insights into the early detection of breast cancer in Russia.MethodsIncidence data from two cancer registries in Russia and 12 population-based cancer registries in Germany were used to analyse breast cancer incidence rates among women above age 30 over time. Further, we calculated rate ratios to compare the age group-specific incidence rates after the implementation of MSP in Germany (2010–2014) with the period before implementation (2003–2005) separately for each tumour stage and all stages combined.ResultsDuring the study period from 2003 to 2014, age-standardised rates for breast cancer were 54.6 and 116.7 per 100,000 for Russia and Germany, respectively. The proportion of the T1 stage at diagnosis among Russian women aged 50 + is half than that in Germany. Nevertheless, we observed an increasing trend of early-stage alongside the reduction of advanced-stage incidence rates of breast cancer in Russia.ConclusionsThe observed trend in Russia may reflect overall positive changes in early detection of breast cancer, with actual proportion of T1 stage still far behind Germany. Advances in breast cancer screening efforts through the dispanserizatsiya may help to further reduce the breast cancer burden. |
| |
| Keywords: | Breast cancer Stage at diagnosis Russia Germany |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
